Cystatin <scp>C</scp> identifies cardiovascular risk better than creatinine‐based estimates of glomerular filtration in middle‐aged individuals without a history of cardiovascular disease

Abstract

Cystatin C is a better risk marker for CVD morbidity and mortality than creatinine-based GFR. Whether this is explained by cystatin C being a better marker for true GFR or through other effects of cystatin C remains to be shown.